Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2013

View Archived Issues

Investigation of EPAC as a therapeutic target expands

A novel fusion protein inhibits IgE-mediated peanut allergy anaphylaxis in vitro and in vivo

French researchers design novel immunocytokines

ATR kinase inhibitors patented by Vertex Pharmaceuticals

Metabolys divulges novel glucose-lowering agents

Novel tyrosine-protein kinase SYK inhibitors reported in Takeda patent

Novartis patent reveals p53/Mdm2 interaction inhibitors

Incyte reports development of novel JAK inhibitors

TRPM7 inhibitors reported in NoNO patent

NIH launches program to find biomarkers for Parkinson's disease

Paladin Labs enters into agreement for novel neuroblastoma drug

QRxPharma and FDA confirm steps for resubmission of MoxDuo NDA

FDA will not meet action date for Ravicti NDA

FDA grants priority review for afatinib in NSCLC with an EGFR mutation

DTRA award supports PsiOxus' development of biodefense vaccine adjuvants

Health Canada approves Afinitor for advanced breast cancer

Novel inhibitor of JMJD2 histone demethylases reduces viral reactivation in vivo

siRNAs against serotonin 5-HT1A receptors produce antidepressant-like effects

Enrollment open in phase II study of Bendavia

Promising topline results from proof-of-concept burns trial of human skin substitute

FDA approves Protein Sciences' Flublok seasonal influenza vaccine

AT-13148 begins U.K. phase I study for cancer

Somatuline launched in Japan

Topline results from phase III heart failure study of Aranesp reported

Pierre Fabre and Maruho sign Japanese licensing agreement for pediatric beta-blocker

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...